Agentix Past Earnings Performance
Past criteria checks 0/6
Agentix has been growing earnings at an average annual rate of 8.5%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been declining at an average rate of 91.2% per year.
Key information
8.5%
Earnings growth rate
14.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -91.2% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Agentix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | 0 | 0 | 0 |
| 31 Mar 24 | 0 | -1 | 1 | 0 |
| 31 Dec 23 | 0 | -1 | 1 | 0 |
| 30 Sep 23 | 0 | -1 | 1 | 1 |
| 30 Jun 23 | 0 | -2 | 1 | 1 |
| 31 Mar 23 | 0 | -1 | 1 | 1 |
| 31 Dec 22 | 0 | -3 | 2 | 1 |
| 30 Sep 22 | 0 | -3 | 2 | 0 |
| 30 Jun 22 | 0 | -3 | 2 | 0 |
| 31 Mar 22 | 0 | -3 | 2 | 0 |
| 28 Feb 22 | 0 | -3 | 2 | 0 |
| 30 Nov 21 | 0 | -1 | 1 | 0 |
| 31 Aug 21 | 0 | -1 | 1 | 0 |
| 31 May 21 | 0 | -1 | 0 | 0 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
Quality Earnings: AGTX is currently unprofitable.
Growing Profit Margin: AGTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AGTX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare AGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: AGTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.